Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo
| | |

Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo

On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO(molnupiravir), an investigational oral antiviral COVID-19…

Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
| | | | |

Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant

On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…

Resilience collaborated with Children’s Hospital of Philadelphia to develop next-gen biomanufacturing technologies
| | | | | | | |

Resilience collaborated with Children’s Hospital of Philadelphia to develop next-gen biomanufacturing technologies

On Oct. 12, 2021, National Resilience announced a strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to implement…